The Ozempic Shortage Is Over

US food And the administration of the drug Has been determined That Semglutide No more ShortageA step that will affect patients’ cheap, synthesized versions of the drug.

Semaglutide, active material Navo Nordisk Blockbuster diabetes and weight loss ations Ozampic and WagoviHave been Of the FDA List of deficiency since March 2022. Could not keep up with the supply Intense demand for drugsWhich reached such a playful level of popularity that it converted to Novo Nordisk into one of the most valuable organizations in the world, with it A market capital Denmark’s own country is bigger than the rest of the economy.

In the middle years, A profitable industry Telefelt agencies, medical spa and pharmacies “Compound” creates and sell copies The drug has emerged. These off-brand copies are sold in steep discounts-sometimes under one dew is compared to the name-brand drugs, which can be more than $ 1000 a month without insurance.

At the end of October, the FDA changed the location of all the doses of Ozempic and Wagovi to “available”, indicating that the end of the government deficit was probably visible. To today, about four months later, the controllers reached the conclusion that the drug was available enough to remove from the crisis list.

FDA Giving The compounds of “503”, usually the state-licensed pharmacy or physician compounds that run small operations, stop the drug production by April 22. It is giving “503B” compounds, which followed the greater outsourcing facility by following the strict production guidelines until May 22.

In general, it is not especially controversial when drugs come from the crisis list. However, there is reason to believe that players in this industry will return to the announcement.

A well -established practice of drug compounds; Pharmacists are allowed to create a copy of the drug when there is a shortage of drugs or when patients need versions made at certain doses or without allergen. However, the GLP -1 boom has created an opportunity for compounds that transform the pockets of the industry, probably for several million patients, pharmacies create a copy of the brand.

Robert McArter, a pharmacy director of Rockefeller University Hospital, said that once a drug came out of the FDA crisis list, pharmacies that create a large batch of complex drugs for healthcare facilities are not supposed to mix outsourcing pharmacy and that drug. However, for small, traditional compound compound pharmacies that produce drugs for home use, it is a legal gray area.

“If the physician writes a prescription for a separate patient and thinks that the patient needs that particular compound product,” McArter says. This reason may adjust the dose or make the drug to a certain patient.

Some telehial decorations have indicated their intention to continue their product supply. “Now that the FDA has resolved the drug deficit for semaglutide, we will continue to offer access to personalized treatment as approved by the law to meet the needs of the patient,” the founder and CEO of Andrew Doodum, Hems and Hales Health, Wrote To X, add that the company is closely monitoring the potential future deficiencies.